Introduction and Corporate Overview

With Renée Aguiar-Lucander, CEO

Pathophysiology of IgA nephropathy & Nefecon Clinical Biomarker Data and A Review of and Commentary on the Phase 3 NefIgArd Trial Data

With Professor Jonathan Barratt, KOL and Dr Richard Philipson, CMO

Regulatory Review of Nefecon

With Frank Bringstrup, Vice President of Regulatory Affairs

Market Access & Preparations for Commercialization in the USA

With Andrew Udell, Head of North America Commercial and Christopher Ngai, Vice President Market Access

Overview of NOX Inhibitors

With Dr Philippe Wiesel, Calliditas’ Medical Advisor

Setanaxib – Applications in Oncology

With Professor Gareth Thomas, KOL

Clinical Development – Pipeline Review

With Dr Richard Philipson, CMO

Positioning Overview

With Renée Aguiar-Lucander, CEO

Closing Summary

With Renée Aguiar-Lucander, CEO and Fredrik Johansson, CFO

KOL Biographies:

Professor Jonathan Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research interests span a range of areas across renal medicine and include glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network. He is also a Chief Investigator for five international randomized controlled clinical trials in IgA nephropathy, and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group.

Professor Gareth J. Thomas is Chair and Professor of Experimental Pathology at University Hospital Southampton NHS Foundation. He leads a group that investigates the effect of the tumor microenvironment on tumor development and progression, particularly the role of cancer-associated fibroblasts in regulating immune escape and tumor invasion. Prior to his current position, Gareth Thomas was Professor of Oral Pathology and Consultant in Oral and Maxillofacial Pathology at Bart’s and the London. Gareth Thomas trained in Oral & Maxillofacial Pathology at University College Hospital, London and undertook his PhD as an MRC Clinical Fellow at University College London and the Richard Dimblebey Department of Cancer Research.